Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid

Cancer Prevention Research

Volumn 1, Issue 3, 2008, Pages 208-214

  Brown, Powel H ^a   Subbaramaiah, Kotha ^b   Salmon, Amoi P ^b,c   Baker, Rebecca ^b,c   Newman, Robert A ^d   Yang, Peiying ^d   Zhou, Xi Kathy ^b   Bissonnette, Reid P ^e   Dannenberg, Andrew J ^b   Howe, Louise R ^b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEXAROTENE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ICOSANOID; PYRAZOLE DERIVATIVE; RETINOID; RETINOID X RECEPTOR; SULFONAMIDE; TETRALIN DERIVATIVE;

ANIMAL; ARTICLE; CARCINOMA; CELL TRANSFORMATION; CHEMOPROPHYLAXIS; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; ENZYME SPECIFICITY; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; METABOLISM; METHODOLOGY; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; PHYSIOLOGY; PROTO ONCOGENE; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; CHEMOPREVENTION; CYCLOOXYGENASE 2 INHIBITORS; DRUG EVALUATION, PRECLINICAL; EICOSANOIDS; FEMALE; GENES, ERBB-2; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; PYRAZOLES; RETINOID X RECEPTORS; RETINOIDS; SUBSTRATE SPECIFICITY; SULFONAMIDES; TETRAHYDRONAPHTHALENES;

EID: 54149115973     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0021     Document Type: Article

References (55)

1. Howe LR. Inflammation and breast cancer. Cyclooxygenase/ prostaglandin signaling and breast cancer. Breast Cancer Res 2007;6:210.
2. Howe LR. Cyclooxygenase-2 and breast cancer. In: Yao AP, editor. Trends in breast cancer research. New York: Nova; 2005. p. 1-38.
3. Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 2004;90:423-9.
4. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62: 632-5.
5. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/ neu-positive breast cancer. Evidence for involvement of AP-1 and PEA3. J Biol Chem 2002;277:18649-57.
6. WulfingP, Diallo R, Muller C, et al. Analysis of cyclooxygenase- 2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol 2003;129:375-82.
7. Denkert C, Winzer KJ, Muller BM, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003;97:2978-87.
8. Spizzo G, Gastl G, Wolf D, et al. Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer 2003;88:574-8.
9. Friedman GD, Ury HK. Initial screeningfor carcinogenicity of commonly used drugs. J Natl Cancer Inst 1980;65:723-33.
10. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase- 2 (COX-2) inhibitors. BMC Cancer 2006;6:27.
11. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003;63:6096-101.
12. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996;7:203-5.
13. Khuder SA, Mutgi AB. Breast cancer and NSAID use: ameta-analysis. Br J Cancer 2001;84:1188-92.
14. Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M. Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer 2005;5:159.
15. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-46.
16. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 2000; 83:112-20.
17. Terry MB, Gammon MD, ZhangFF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004;291:2433-40.
18. Hamid R, Singh J, Reddy BS, Cohen LA. Inhibition by dietary menhaden oil of cyclooxygenase-1 and -2 in N-nitrosomethylurea-induced rat mammary tumors. Int J Oncol 1999;14:523-8.
19. Howe LR, Crawford HC, Subbaramaiah K, Hassell JA, DannenbergAJ, Brown AMC. PEA3 is up-regulated in response to Wnt1 and activates the expression of cyclooxygenase-2. J Biol Chem 2001;276:20108-15.
20. Howe LR, Subbaramaiah K, Patel J, et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 2002;62:5405-7.
21. Nakatsugi S, Ohta T, Kawamori T, et al. Chemoprevention by nimesulide, a selective cyclooxygenase- 2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res 2000;91: 886-92.
22. Robertson FM, Parrett ML, Joarder FS, et al. Ibuprofen- induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett 1998;122: 165-75.
23. Lanza-Jacoby S, Miller S, Flynn J, et al. The cyclooxygenase- 2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol Biomarkers Prev 2003;12: 1486-91.
24. Howe LR, ChangSH, Tolle KC, et al. HER2/neuinduced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 2005;65:10113-9.
25. Liu CH, ChangSH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001; 276:18563-9.
26. ChangSH, Liu CH, Conway R, et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced br east cancer progression. Proc Natl Acad Sci U S A 2004;101: 591-6.
27. Muller-Decker K, Berger I, Ackermann K, et al. Cystic duct dilatations and proliferative epithelial lesions in mouse mammary glands upon keratin 5 promoter-driven overexpression of cyclooxygenase- 2. Am J Pathol 2005;166:575-84.
28. Subbaramaiah K, Howe LR, Port ER, et al. HER- 2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase- 2-dependent mechanism. Cancer Res 2006; 66:5504-11.
29. Bertagnolli MM. Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. Lancet Oncol 2007;8:439-43.
30. Bresalier RS. Chemoprevention of colorectal neoplasia: advances and controversies (the COX-2 story). Curr Opin Gastroenterol 2007;23: 44-7.
31. Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 2007; 7:357-69.
32. Steele VE, Kelloff GJ. Development of cancer chemopreventive drugs based on mechanistic approaches. Mutat Res 2005;591:16-23.
33. DannenbergAJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005; 23:254-66.
34. Lippman SM, Lotan R. Advances in the development of retinoids as chemopreventive agents. J Nutr 2000;130:479S-82S.
35. Moon RC, Mehta RG, Rao KVN.Sporn MB, Roberts AB, Goodman DS. Retinoids and cancer in experimental animals. The retinoids: biology, chemistry and medicine. 2nd ed. New York: Raven Press; 1994. p. 573-95.
36. Howe LR. Rexinoids and breast cancer prevention. Clin Cancer Res 2007;13:5983-7.
37. Miller VA, Benedetti FM, Rigas JR, et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997;15:790-5.
38. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 1996;56: 5566-70.
39. Liby K, Rendi M, Suh N, et al. The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. Clin Cancer Res 2006;12: 5902-9.
40. Wu K, ZhangY, Xu XC, et al. The retinoid X receptor- selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 2002;62:6376-80.
41. YangP, Chan D, Felix E, et al. Determination of endogenous tissue inflammation profiles by LC/ MS/MS: COX- and LOX-derived bioactive lipids. Prostaglandins Leukot Essent Fatty Acids 2006; 75:385-95.
42. Wu K, Kim HT, Rodriquez JL, et al. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev 2002;11:467-74.
43. Kim HT, KongG, Denardo D, et al. Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells usingolig onucleotide arrays. Cancer Res 2006; 66:12009-18.
44. KongG, Kim HT, Wu K, et al. The retinoid X receptor- selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res 2005;65:3462-9.
45. Brodie AM, Lu Q, LongBJ, et al. Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol 2001;79:41-7.
46. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999; 140:27-35.
47. Agarwal VR, Bulun SE, Leitch M, Rohrich R, Simpson ER. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J Clin Endocrinol Metab 1996;81:3843-9.
48. Chen S, Zhou D, Okubo T, Kao YC, YangC. Breast tumor aromatase: functional role and transcriptional regulation. Endocr Relat Cancer 1999;6:149-56.
49. Diaz-Cruz ES, Shapiro CL, Brueggemeier RW. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 2005;90:2563-70.
50. Prosperi JR, Robertson FM. Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumor cells. Prostaglandins Other Lipid Mediat 2006;81:55-70.
51. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leadingt o activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996; 137:5739-42.
52. Rubin GL, DuongJH, Clyne CD, et al. Ligands for the peroxisomal proliferator-activated receptor γ and the retinoid X receptor inhibit aromatase cytochrome P450 (CYP19) expression mediated by promoter II in human breast adipose. Endocrinology 2002;143:2863-71.
53. ZhangX, Podsypanina K, Huang S, et al. Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations. Oncogene 2005;24:4220-31.
54. Mann M, ShengH, Shao J, et al. Targetingcyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001;120:1713-9.
55. Grubbs CJ, Lubet RA, Atigadda VR, et al. Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers. Carcinogenesis 2006;27:1232-9.